Connect with us

Politics

Federal Officials Give Hemp Legalization Update At Senate Hearing

Published

on

The Senate Agriculture Committee heard from federal agencies about efforts to implement the legalization of hemp at a hearing on Thursday.

In the months since the crop and its derivatives were federally legalized under the 2018 Farm Bill, lawmakers and industry stakeholders have made repeated calls to expedite the development of regulations providing for the lawful marketing of hemp products.

The panel requested updates to that end from invited witnesses, which included representatives of the U.S. Department of Agriculture (USDA), Food and Drug Administration (FDA) and Environmental Protection Agency (EPA).

Agriculture Committee Chairman Pat Roberts (R-KS) said the hearing was meant to provide “certainty and predictability for farmers” and that “this developing industry has great opportunity but—to be truthful—also has much uncertainty and risk for farmers.”

“There are complex questions in this space. Is hemp the crop of a generation? What will this industry look like in 10 years?” he said. “I do not know the answers to these questions, and I am not sure if anyone actually can answer them.”

Sen. Debbie Stabenow (D-MI), the committee’s ranking member, discussed the history of hemp in the United States, calling it a “new, old crop” that is part of a “great American tradition.”

Noting that founding fathers like George Washington, John Adams and Thomas Jefferson all grew hemp, she joked that “maybe Lin-Manuel Miranda will make his next musical about that,” referring to the “Hamilton” creator.

“We also need to ensure that these new opportunities in hemp production are fair and equitable for all farmers,” she said on a more serious note. “Given the USDA’s troubling history of discrimination, the Department must be proactive to ensure socially-disadvantaged farmers have the same opportunity to get a license to grow hemp. It’s also critical that there is fair testing and enforcement of harvested hemp across the board.”

Witnesses on the first panel at the hearing included USDA Under Secretary for Marketing and Regulatory Programs Greg Ibach, USDA General Counsel Stephen Vaden, FDA Principal Deputy Commissioner of Food and Drugs Amy Abernethy and EPA Office of Chemical Safety and Pollution Prevention Assistant Administrator Alexandra Dunn.

The second panel consisted of National Hemp Association Executive Director Erica Stark, Red Lake Band of Chippewa Indians Tribal Chairman Darrell Seki and Kentucky farmer Brian Furnish.

Watch the hearing below:

Thursday’s hearing marks the second congressional cannabis-related meeting of the week after the Senate Banking Committee convened on Tuesday to discuss banking issues in the broader marijuana industry.

Even after hemp’s legalization, lawmakers and industry participants have raised concerns about ongoing problems accessing financial services businesses involved with the crop and its derivatives, some of which have said they’ve been denied credit lines and insurance policies due to a lack of guidance from federal regulators. That issue also came into play during Thursday’s hearing.

While few GOP senators attended the week’s earlier marijuana-focused meeting, hemp has garnered strong bipartisan support and this hearing reflected that shared political interest. Senate Majority Leader Mitch McConnell (R-KY) has been a particularly vocal proponent of the crop, shepherding his hemp legalization provision to passage as part of the large-scale agriculture legislation that was signed by President Donald Trump in December.

McConnell made an appearance and said that he’s “glad” the crop is “making a comeback, and it’s generated incredible excitement all across my state.” He noted that it is being grown in 101 out of 120 counties in Kentucky.

“This product is incredible—from food to clothing to wellness products, what a diversified product,” he said, adding that there are some remaining issues that need to be resolved. Those issues include ensuring that hemp farmers have access to crop insurance and financial services.

McConnell led Agriculture Secretary Sonny Perdue on a tour of a Kentucky hemp farm earlier this month and also met with Acting FDA Commissioner Ned Sharpless, advising the official to create a pathway for CBD to be lawfully marketed in food items and dietary supplements. Former Commissioner Scott Gottlieb said that developing such regulations could take years absent congressional action.

FDA’s Abernethy recognized in her testimony that a multi-year process for rules to be developed “is a long time to wait for regulatory clarity, particularly given the significant public interest in hemp products, and CBD in particular.” FDA said earlier this month that it is speeding up its rulemaking effort for CBD, adding that it plans to issue a status update by early fall.

The official acknowledged that the Farm Bill “unleashed a wave of interest and innovation in hemp agriculture” and stressed “how significant of a policy sea change this has been.”

Abernethy said that “FDA’s approach to cannabis and cannabis derived products, including hemp products, is to treat these products just like we do any other.”

“FDA is committed to advancing hemp products through the Agency’s existing regulatory pathways, and we are further exploring whether it would be appropriate to make additional regulatory pathways available to hemp products such as those containing cannabidiol (CBD). FDA believes taking this approach protects patients and the public health, fosters innovation for safe and appropriate products, and promotes consumer confidence.”

She went on to say that FDA is “wrestling with questions not only about the intrinsic safety of CBD, but also about potentially unsafe manufacturing processes for products containing CBD.”

“FDA knows from CBD products it has tested that they may not contain the amount of CBD indicated on a label, or they may contain other potentially dangerous compounds that are not listed on the label,” she said. “Therefore, FDA must consider questions related to good manufacturing practices for CBD products and potential labeling that might be appropriate for these products to address any potential risks to consumers.”

Further, Abernethy described the complications the agency faces as it considers allowing for the lawful marketing of CBD products in the food supply or as dietary supplements. She suggested FDA would have to create exceptions for hemp under all of its regulations because carving out just one exception could “end up generating additional confusion in the marketplace—a result the Agency believes all stakeholders would prefer to avoid.”

“FDA will only consider creating legal pathways for CBD to be marketed as a dietary supplement or in a food if the Agency is confident that it can develop a framework that addresses safety concerns,” she said.

“Another issue that FDA plans to consider is whether allowing CBD to be marketed as a dietary supplement or in a food will deter clinical research to substantiate additional therapeutic uses for cannabis-derived compounds,” Abernathy added. “Less research into the promise of cannabis-derived compounds and fewer drug approvals in this area would be a significant loss for American patients.”

She also said that confusion generated from the legalization of hemp and its derivatives has led some companies to engage in interstate commerce and that “storefronts and online retailers have flooded the market with these products, many with unsubstantiated therapeutic claims.” Just this week, FDA sent a warning letter to CBD business Curaleaf for selling “unapproved products with unsubstantiated therapeutic claims,” sending the company’s stock plummeting.

“As this new market emerges, we have seen substantial interest from industry, consumers, and Congress,” she said. “However, in the midst of the excitement and innovation, FDA’s role remains the same: to protect and promote the public health.”

USDA, for its part, initially said that it was aiming to release an interim final rule for hemp in August, but the Department’s Ibach said in his testimony that while officials are “committed to timely establishment of this program,” the rule “is currently undergoing interagency review and we hope to issue regulations in the Fall of 2019 to accommodate the 2020 crop year.”

“Once the regulation is published and becomes effective, [Agriculture Marketing Service] will move quickly to establish the program,” Ibach said. “AMS will begin accepting and reviewing state and tribal plans as well as license applications submitted by individuals who are located in States or territories of Indian Tribes that will not operate their own State or Tribal plan, and who wish to be licensed under the USDA plan.”

EPA’s representative discussed the agency’s role in approving pesticides for hemp plants, saying that officials anticipate that “pesticide registrants will intensify their interest in gaining crop protection approvals for use” on the crop thanks to “strong economic forecasts for hemp production.

“I can report that the agency has recently begun to receive a number of registration requests seeking to add hemp to pesticide labels,” Dunn said. “Currently, there are 10 product registration requests under review at the EPA.”

Dunn also said that the agency is prioritizing and reviewing on an expedited basis requests involving biological and microbial chemicals because they tend to have a low environmental impact.

“I anticipate these will be the first of a group of decisions that will support growers and this new industry,” she said.

An interagency dialogue is underway across EPA, USDA, FDA and the Justice Department, she said. Additionally, EPA is “also in discussions with the Health Canada Pest Management Regulatory Agency about their approved pesticide labels and approaches to regulating hemp.”

During the second panel, Furnish, who was one of the first hemp farmers in Kentucky, talked about the potential of the hemp industry but also the unique risks that cultivators face.

Since the crop is now legal, “we need to take a close look and remove, one by one, the barriers to success so hemp can be on the same production playing field as all the other crops,” he said.

He also brought up part of Dunn’s testimony and emphasized the lack of EPA-approved pesticides for hemp.

“Most folks in the government and even in production agriculture probably don’t know or realize that hemp has no legal pesticide or herbicide or fungicide,” Furnish said. “A grower can lose its entire crop to weeds or pests. Without an approved herbicide or pesticide we may have to pay labor between $500 – $2500 an acre to pull the weeds to keep our hemp crop pure and healthy.”

Echoing a point that his home state senator, McConnell, has made on numerous occasions, he said hemp stands to be an economic benefit to Kentucky as tobacco farming dwindles.
“The labor necessary to successfully plant and harvest hemp is much the same as tobacco,” Furnish said. “That’s why hemp is and can be a great replacement for the dwindling tobacco production.”

“Corn, wheat and soybeans all have hundreds and maybe thousands of product uses. Hemp can too, but they need the barriers removed and the consistency and stabilization which come from the regulatory framework you all can give us. On behalf of the hemp farmers and growers, I’m asking for that help.”

The farmer also cited the lack of crop insurance and uncertainty about whether FDA will allow hemp derivatives in foods and dietary supplements as issues that lawmakers can help address.

Tribal Chairman Seki argued that USDA has left native populations out of the rulemaking process and he implored the department to take a more inclusive approach as it develops regulations for hemp, saying that officials have “frequently mischaracterized the sovereignty of Indian Tribes in the context of industrial hemp regulation under the 2018 Farm Bill.”

“Despite significant progress in the Farm Bill itself for Tribal sovereignty, USDA decisions to delay regulations are threatening to cripple Tribal industrial hemp projects before they can even begin,” he said. “If Tribes had always been on the same footing with states in terms of growing and regulating industrial hemp, this regulatory delay would merely be a source of frustration. Instead it poses a serious threat to competitive Tribal agribusiness.”

“The legalization of industrial hemp production marks a potential landmark economic opportunity for Tribes and Tribal producers through value-added agriculture. Because of this, it is vital that federal policymakers and agency officials negotiate with Tribal leaders, in robust government-to-government consultation, in shaping the federal regulatory structure implementing the industrial hemp provisions of the 2018 Farm Bill. This commitment must be made real from top to bottom at USDA. Otherwise, there is a high risk of this turning into yet another missed opportunity for Indian Country.”

A USDA memo released in May asserted that Indian tribes can engage with states that have approved hemp research programs authorized under the prior 2014 Farm Bill but they can’t authorize such programs themselves. Seki said it reflects a lack of inclusivity that native tribes are grappling with as states continue to move forward on hemp without the same restrictions.

He also decried delays in implementation, saying that “the more the AMS delays, the less time Tribal producers are given to prepare, plan, finance, and plant for the new crop year.”

Stark, of the National Hemp Association, said that the industry is in particular need of clarification when it comes to testing protocols, sampling, personnel eligibility requirements, cross-pollination and the importation of biomass.

“At the very heart of what we need to move forward is simplicity and clarity,” she said. “We need regulations that create an even playing field across the country. We need to eliminate the unintended consequences of legal ‘gray areas’ caused by each state testing differently and operating under a different set of rules and regulations.”

“The hemp industry has been struggling with legal uncertainties for too long and looks forward to reasonable regulations which will afford the opportunity for all to prosper within a clear legal framework,” she said.

While advocates have cast doubts on interest within the Republican-controlled Senate to pursue broader marijuana reform, hemp is one area where lawmakers from both parties have expressed support. And that sentiment was made clear during Thursday’s hearing.

Kentucky GOP Congressman Touts ‘High Hemp IQ’ Of His Constituents

Photo courtesy of Pixabay.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Politics

Missouri Marijuana Legalization Campaign In Jeopardy Due To Coronavirus

Published

on

Coronavirus has dealt another blow to the marijuana reform movement. This time, activists in Missouri announced on Saturday that their effort to put a cannabis legalization measure on the ballot has “no practical way” of succeeding amid the pandemic.

In recent weeks, the outbreak of COVID-19 has resulted in business closures and increased calls for social distancing in states across the country. That has made mass signature gathering for drug policy reform measures virtually impossible.

“Unfortunately, while there is widespread support from Missourians to tax and regulate marijuana, there is currently no practical way during the COVID-19 outbreak to safely, publicly gather the 170,000 plus signatures needed over the remaining 6 weeks to put this on the Missouri ballot in 2020,” John Payne, campaign manager for Missourians for a New Approach, said.

He added that the group is still “exploring our options at this point” but if it ultimately cannot find a path to the ballot for this November, “our supporters from every corner of this state will be back next cycle to put this on the 2022 ballot and finally bring Missouri the benefits of a safe, adult-use marijuana program.”

A total of 160,199 valid signatures from registered voters are needed in order to qualify the measure for this year’s ballot, and the campaign says it has so far collected roughly 80,000—though it is unclear how many of those have been validated. Organizers have aimed to collect more than needed in case some submissions are not accepted.

In a separate email circulated to supporters earlier on Saturday, Dan Viets, coordinator for Missouri NORML and an advisory board member for Missourians for a New Approach, said the “status of the effort to legalize adult use of marijuana in Missouri this year is unclear.”

“No official decision has yet been made regarding whether to suspend the campaign,” he said. “If we do so, it is likely we will return to pursue this goal in 2022.”

“It is, of course, virtually impossible to effectively gather signatures on petitions given the response to the coronavirus pandemic. Gatherings of more than a very few people in any one place have been banned. Almost all colleges and universities have switched to online teaching. No large meetings, conferences, or other gatherings are taking place. We should know within a very short time whether the campaign will be continuing this year or not.”

The language of the campaign messages indicates that activists aren’t entirely throwing in the towel just yet. But that’s a change of tone compared to a message sent to key organizers earlier this month by Graham Boyd, director of the national New Approach PAC, which has been a chief funder of the Missouri effort.

Boyd wrote in the March 17 email obtained by Marijuana Moment that after “much deliberation, we’re making the very difficult, but ultimately unavoidable, decision to end our 2020 adult-use legalization effort in Missouri.”

“As you can imagine, the onset of the coronavirus situation has made that already difficult process essentially impossible,” he said at the time, adding that after discussing the issue with reform campaigns in other states, it “seems likely that the situation will get much worse in many more states before it gets better.”

Since then, organizers have worked to try to salvage the effort.

Activists officially started signature gathering for the Missouri campaign in January, and they were optimistic that voters in the state would embrace the reform move. The proposed initiative would allow adults 21 and older possess and purchase cannabis from licensed retailers and cultivate up to three plants for personal use.

Additionally, it would impose a 15 percent tax on marijuana sales, with revenue going toward veterans services, substance misuse treatment and infrastructure projects. Individuals with cannabis convictions would be empowered to petition for resentencing or expungements.

Boyd stressed in his email that cancelling the campaign would be a “temporary setback” and that it’s “clear from the work and polling we’ve done so far that voters in Missouri are ready to approve a marijuana legalization law.”

Beyond Missouri, coronavirus has already proven to be a formidable presence in 2020 politics, with multiple drug policy reform campaigns having been impacted by the public health crisis.

Activists in California recently released a video asking California officials to allow digital signatures for a petition to revise the state’s adult-use marijuana program. In Washington, D.C., advocates for a measure to decriminalize psychedelics similarly wrote to the mayor and local lawmakers, imploring them to accept online signatures for their ballot petition.

Another California campaign to legalize psilocybin mushrooms is struggling and asking for electronic signature gathering to qualify for the ballot. An effort to legalize medical cannabis in Nebraska is facing similar signature gathering challenges.

In Oregon, advocates for a measure to decriminalize drug possession and a separate initiative to legalize psilocybin for therapeutic purposes have suspended in-person campaign events amid the pandemic.

Arizona activists shared some more positive news this week, however, announcing that they have collected more than enough signatures to qualify for the state’s November ballot—though they have not yet been submitted to or verified by the state.

Arizona Marijuana Activists Have More Than Enough Signatures To Put Legalization On Ballot, They Say

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Scientists Sue DEA Over Alleged ‘Secret’ Document That Delayed Marijuana Research Expansion

Published

on

The Drug Enforcement Administration (DEA) is finding itself in court over marijuana again after scientists filed a lawsuit against the agency, requesting “secret” documents that they allege DEA used to delay action on expanding cannabis research.

The Scottsdale Research Institute (SRI) is behind the suit. It’s one of more than 30 organizations that have submitted applications to DEA to become licensed cannabis manufacturers for research purposes.

Some background should be noted: In 2016, DEA announced it would expand marijuana research by approving additional growers beyond the sole source that has existed for half a century at the University of Mississippi. But after more than three years, applicants heard silence, and SRI filed an initial lawsuit alleging that the agency was deliberately holding up the process. A court mandated that it take steps to make good on its promise, and that case was dropped after DEA provided a status update.

This month, DEA finally unveiled a revised rule change proposal that it said was necessary due to the high volume of applicants and to address potential complications related to international treaties to which the U.S. is a party. A public comment period is now open, after which point the agency says it will finally approve an unspecified number of additional growers.

But what really accounted for the delay?

According to the plaintiffs in this new suit, after DEA said it would accept more cultivators, the Justice Department’s Office of Legal Counsel (OLC) secretly issued an opinion that interprets international treaty obligations as making it impossible to carry out the 2016 proposed rule while maintaining compliance.

The new revised rule aims to address the problem, in part by shifting jurisdiction over the cannabis to a single agency, DEA, which would purchase and technically own all of the cannabis grown by approved cultivators, and would then later sell the product directly to researchers.

That OLC document, which is not public, is the basis of SRI’s Freedom of Information Act (FOIA) complaint. The case was filed with the U.S. District Court for the District of Arizona on Wednesday and requests that the Justice Department be found guilty of unlawfully failing to make records available related to its interpretation of the Single Convention treaty, including the OLC opinion. It further states that DEA should release those documents and pay the plaintiff’s attorney fees.

Matt Zorn, an attorney working the case, told Marijuana Moment in a phone interview that it’s not clear what’s contained in the OLC opinion and that the uncertainty is “entirely the point” of the suit.

“I think we all know vaguely what it says—the subject matter of it—but we don’t know what it actually says,” he said. “That’s important because you need to know what that instruction was or what their interpretation of the law is to assess whether what they’re doing now is appropriate.”

The suit claims that SRI, “as a non-commercial company dedicated to advancing the state of medical care through clinical research, is directly harmed by this unlawful secrecy.”

“Because Defendants have failed to fully disclose their re-interpretation of federal law and treaty obligations as the law requires, Plaintiff lacks information necessary to protect its legal rights, including the right to have its application to manufacture marijuana for research processed in compliance with the Administrative Procedure Act and the [Controlled Substances Act],” the filing states.

SRI’s research objective for cannabis is to determine potential therapeutic benefits for veterans suffering from conditions such as post-traumatic stress disorder. “While DEA’s unlawful and dilatory conduct harms the public generally, the secrecy and delay have been especially harmful to our nations’ veterans,” the suit says.

“We deserve not only to know the scientific truth about medical marijuana use, but candor from our government, which includes disclosure of the ‘secret law’ the agency continues to rely on as a basis to delay and ultimately revamp the process for researching and manufacturing marijuana in this country,” the filing says. “Plaintiff brings this FOIA action so can understand the legal basis—if there is one—for the government’s conduct surrounding the Growers Program.”

While SRI acknowledged that DEA last week announced its revised rule change proposal, the suit states that the explanation about how it arrived at its determination “leaves Plaintiff and the public in the dark with respect to several critical considerations.” For example, it alleges, the notice doesn’t account for how the Justice Department advised the agency on the matter and which parts of the amended proposal would make the action compliant with international treaties.

“The answer to these questions and others presumably lies in the undisclosed OLC Opinion and related records that animated DOJ’s decision to sideline the Growers Program and prompted DEA to embark on this notice-and-comment rulemaking in the first place… In sum, using a secret OLC Opinion interpreting the CSA and a 1961 international treaty, DEA delayed processing applications to cultivate marijuana for research and now proposes to radically revamp federal law through rulemaking—rules which will loom large over the future of medical marijuana research, manufacture, and distribution going forward.”

The plaintiffs argue that DEA violated federal statute that prohibits the creation of a “secret law.” The statute says that federal agencies must make records—including final opinions and policy interpretations not published in the Federal Register—public.

“To block the Growers Program, DOJ formulated—through the OLC Opinion and related records—and DEA adopted to an undisclosed interpretation of the Single Convention and federal law contrary to the view espoused and published by DEA in the August 2016 Policy Statement, and contrary to the view of the State Department,” it continues, apparently referencing a letter the State Department sent to a senator in response to questions about the role of international treaties as it concerns expanding cannabis cultivation facilities.

In that letter, the department said nothing about the Single Convention prevents member nations from increasing the number of such facilities. “If a party to the Single Convention issued multiple licenses for the cultivation of cannabis for medical and scientific purposes, that fact alone would not be a sufficient basis to conclude that the party was acting in contravention of the Convention,” it read.

Read the State Department’s responses on international treaties and marijuana below:

State Dept Response on Single Convention by Marijuana Moment on Scribd

If the new lawsuit’s allegations prove accurate, it could help explain the role of former Attorney General Jeff Sessions, the anti-marijuana official who was reportedly involved in blocking research expansion.

The suit, which was first reported by Politico, goes on to say:

“For more than three years, Defendants relied on this undisclosed interpretation, contained in the OLC Opinion and related records, to make an end-run around the Administrative Procedure Act by unlawfully withholding and unreasonably delaying agency action on marijuana cultivation applications. The OLC Opinion has guided DEA’s actions—and its inaction… The government’s unlawful conduct under FOIA prevents Plaintiff and those similarly situated from timely and effectively vindicating legal rights under the Administrative Procedure Act, effectively rendering its protections and judicial review provisions meaningless.”

To resolve the issue, SRI said it wants DEA to be held accountable for violating federal law, release the documents and compensate them for the legal action. While this is a FOIA-related suit, the institute didn’t first seek the documents through a standard document request but instead filed the case under the law’s “Reading Room provision” that allows courts to force federal agencies to put records online, according to a Ninth Circuit ruling last year.

Sue Sisley, a researcher with SRI, told Marijuana Moment that the institute has generally had a good relationship with DEA over the years and doesn’t expect that it would unduly deny their application in retaliation for the institute’s repeated legal actions against the agency.

“I couldn’t fathom that that would happen, but I hope that the merits of our application are so clear that it would carry us forward,” she said. However, these licensing agreements are “not always a merit-based process so it is possible that if politics get deeply involved here that there could be a situation where licenses are awarded to friends of the government. We’re still praying that there is some merit-based system.”

Researchers and lawmakers have made clear that the current availability of federally authorized cannabis for research raises questions about the accuracy of tests that rely on it, as the quality is insufficient. As of now, there’s only one facility at the University of Mississippi that’s authorized to grow cannabis for researchers. The products developed at the university have been widely criticized by scientists and lawmakers. A study indicated that the facility’s cannabis is chemically more similar to hemp than marijuana available in state-legal markets.

“If adopted, these proposed rules would radically overhaul how medical marijuana manufacture and research will proceed in this country,” the plaintiffs wrote. “Better supply is needed for better research, and better research is needed not only because millions use medical marijuana every day, but also to facilitate informed policymaking at the federal and state levels, including legislation and drug scheduling decisions.”

Read the full lawsuit against DEA below:

SRI FOIA Complaint by Marijuana Moment on Scribd

Federal Agency Touts Hemp Progress While Refusing To Serve Marijuana Businesses

Photo courtesy of Mike Latimer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

First Legal Marijuana Home Deliveries Begin In Colorado

Published

on

For the first time, people in Colorado will be able to legally have marijuana products delivered directly to their homes starting on Friday.

The launch of the limited program focused on medical cannabis patients comes one week after the dispensary chain Native Roots announced that its Boulder location The Dandelion had received the state’s first marijuana delivery license. And while the license wasn’t related to the coronavirus outbreak, the timing is opportune, as officials have increasingly cautioned against leaving home to avoid catching or spreading the virus.

The delivery service will be limited to patients living in either Boulder or Superior. They must also be registered with the dispensary, and those who are not already signed up must do so in-person for the time being—though Native Roots said it is “looking into a compliant, remote solution for patient registration.”

Native Roots said there is a $100 minimum purchase, and they’re encouraging patients to pay with a debit card rather than cash, presumably because drivers could be targets of burglaries if they’re transporting large amounts of cash or because of concerns that money changing hands could further the spread of COVID-19.

Cannabis delivery services are a new feature of Colorado’s legal marijuana program. Gov. Jared Polis (D) signed legislation last year allowing the option, though individuals jurisdictions must proactively opt-in, so as of now that number of cities permitting deliveries is limited. Native Roots said it’s been engaging with local governments about the issue for months.

Deliveries for recreational cannabis consumers won’t begin until January 2021 under the law.

As more businesses shutter as a result of the pandemic, there’s growing demand for alternative means of obtaining marijuana products, and several states have taken steps to address that concern by encouraging deliveries and curbside pickup, for example.

For patients and reform advocates, that represents an ideal solution compared to closing dispensaries altogether. Numerous legal states have categorized cannabis shops as essential services that are exempt from mandates to close down. And according to a poll released this week, a majority of Americans agree with that decision.

But while the market remains largely operational in the midst of this health crisis, reform advocates across the U.S. are feeling the impact and struggling to continue campaign activities, including in-person signature gathering.

Campaigns to change state marijuana programslegalize psilocybin mushroomslegalize psilocybin for therapeutic purposeslegalize medical and recreational cannabisdecriminalize psychedelics and broadly decriminalize drug possession have all faced challenges amid the pandemic, and several have implored officials to allow electronic signature gathering to overcome the barrier.

An exception to this appears to be Arizona, where activists recently said they’ve collected more than enough signatures at this point to qualify for the state’s November ballot.

Arizona Marijuana Activists Have More Than Enough Signatures To Put Legalization On Ballot, They Say

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!